RLYB•benzinga•
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
Summary
Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 8, 2025 by benzinga